Navigation Links
BioMS Medical to present at BIO CEO and Investor Conference
Date:2/5/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, Feb. 5 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at The 11th Annual BIO CEO & Investor Conference in New York.

    WHEN:     Monday February 9th at 2:45pm (Eastern Time)

    WHERE:    Waldorf-Astoria, New York City


    About BIO CEO & Investor Conference
    -----------------------------------
    This conference aims to bring together institutional investors, industry
analysts, and senior biotechnology executives in a neutral and collaborative
forum to examine investment opportunities and issues affecting the industry.
For more information visithttp://ceo.bio.org/opencms/ceo/2009/index.jsp.

    About BioMS Medical Corp.
    -------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
2. BioMS Medical recognized at Scrip Awards 2008
3. BioMS Medical Announces Third Quarter 2008 Results
4. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
5. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
8. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
9. BioMS Medical to present at UBS Global Life Sciences Conference
10. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
11. BioMS Medical announces its intention to renew a normal course issuer bid
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/10/2017)... , ... August 09, 2017 , ... ... classroom next week-- as students. From August 14th through the 16th, the University ... which debuted in the summer of 2016, provides Philadelphia-based middle school educators an ...
(Date:8/10/2017)... (PRWEB) , ... August 09, 2017 , ... Each year ... half never recover well enough to live an independent lifestyle and, even worse, the ... A new discovery by doctors at the University of California Davis Medical Center (Sacramento) ...
(Date:8/10/2017)... , ... August 09, 2017 , ... ... four international biomedical optics laboratories — the Wellman Center for Photomedicine, the Manstein ... Center Lübeck and the Beckman Laser Institute at University of California, Irvine — ...
(Date:8/10/2017)... UK (PRWEB) , ... August 10, 2017 , ... ... announced an agreement establishing Kinokuniya Company Ltd. as its exclusive sales representative for ... exclusive sales representative for the SPIE Digital Library in Japan. , “We look ...
Breaking Biology Technology:
(Date:6/30/2017)... , June 30, 2017 Today, ... developer and supplier of face and eye tracking ... Featured Product provider program. "Artificial ... innovative way to monitor a driver,s attentiveness levels ... from being able to detect fatigue and prevent ...
(Date:5/16/2017)... 2017   Bridge Patient Portal , an ... MD EMR Systems , an electronic medical record ... have established a partnership to build an interface ... GE Centricity™ products, including Centricity Practice Solution (CPS), ... These new integrations will allow healthcare delivery networks ...
(Date:4/17/2017)... April 17, 2017 NXT-ID, Inc. (NASDAQ: ... the filing of its 2016 Annual Report on Form 10-K on ... ... is available in the Investor Relations section of the Company,s website ... SEC,s website at http://www.sec.gov . 2016 Year Highlights: ...
Breaking Biology News(10 mins):